CEACAM1 is expressed on the surface of different myeloid cells and lymphocytes and is regarded as a promising target for immunotherapy.[27, 51] CM‐24, a monoclonal antibody targeting CEACAM1, has been evaluated clinically for treating advanced or recurrent cancers,[52] and is currently under early clinical trial for combination with Nivolumab, an anti‐PD1 antibody (NCT04731467). Here, CEACAM1 is linked to cancer.